B. Riley Securities Initiates Coverage On Arcturus Therapeutics with Buy Rating, Announces Price Target of $22
Arcturus Therapeutics +0.11%
Arcturus Therapeutics ARCT | 8.85 | +0.11% |
B. Riley Securities analyst Mayank Mamtani initiates coverage on Arcturus Therapeutics (NASDAQ:
ARCT) with a Buy rating and announces Price Target of $22.
